RIPOR1 and colorectal carcinoma: Mechanistically, we elucidated that FAM65A binds to Ras and activates the Ras/extracellular regulated protein kinases (ERK) signaling to mediate RSK activation contributes to CRC progression, treatment with the Ras inhibitor Abd-7 or RSK inhibitor BRD7389 effectively countered the FAM65A-mediated enhancement of malignancy.